Oxford Biomedica (LON:OXB) Earns "Buy" Rating from Stifel Nicolaus

Key Points

• Stifel Nicolaus reissued a Buy rating with a price target of GBX 950, implying about a 49.14% upside from the current share price.
• Deutsche Bank raised its target to GBX 800; overall analyst coverage shows five Buys and one Hold with a consensus target of GBX 663.67 (rated "Moderate Buy").
• Oxford Biomedica shares recently traded at GBX 637 (down GBX 14), the company has a market cap of £769.95m, a negative P/E of -17.59, and a 12‑month range of GBX 232.50–952.

Oxford Biomedica (LON:OXB - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at Stifel Nicolaus in a note issued to investors on Wednesday,London Stock Exchange reports. They currently have a GBX 950 price objective on the biopharmaceutical company's stock. Stifel Nicolaus' target price suggests a potential upside of 49.14% from the stock's current price.

Separately, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a "buy" rating in a report on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, Oxford Biomedica has an average rating of "Moderate Buy" and a consensus target price of GBX 663.67.

Oxford Biomedica Stock Performance

LON:OXB traded down GBX 14 during trading on Wednesday, reaching GBX 637. The company's stock had a trading volume of 135,453 shares, compared to its average volume of 654,885. The firm has a market cap of £769.95 million, a price-to-earnings ratio of -17.59 and a beta of 1.04. The company has a debt-to-equity ratio of 322.11, a quick ratio of 1.67 and a current ratio of 1.89. The firm has a 50 day moving average of GBX 763.94 and a 200-day moving average of GBX 661.39. Oxford Biomedica has a 12 month low of GBX 232.50 and a 12 month high of GBX 952.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.